# 乙醛脱氢酶2基因rs671位点多态性与化疗所致的恶心呕吐相关

## Metadata
**Authors:** 杨 群, 刘 晓鑫, 蒋 玉娜, 马 进安
**Journal:** Journal of Southern Medical University
**Date:** 2023 Jun 20
**DOI:** [10.12122/j.issn.1673-4254.2023.06.18](https://doi.org/10.12122/j.issn.1673-4254.2023.06.18)
**PMID:** 37439175
**PMCID:** PMC10339303
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339303/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC10339303/pdf/nfykdxxb-43-2023061017.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC10339303/pdf/nfykdxxb-43-2023061017.pdf)

## Abstract

**目的:** 
探寻乙醛脱氢酶2（ALDH2）基因rs671位点单核苷酸多态性与化疗所致恶心呕吐的相关性。

**方法:** 
选择恶性肿瘤首次住院化疗的90例中国患者，多时段观察收集三联止呕方案下患者接受多西他赛联合顺铂化疗方案后120 h内化疗所致恶心呕吐（CINV）的发生情况。问卷采集所有患者的年龄、性别、肿瘤分期、习惯性饮酒、晕动症史、孕吐史、化疗前平均睡眠时间等的资料，并对其ALDH2基因rs671位点进行基因型检测。利用效用程序计算遗传连锁分析Hardy-Weinberg平衡检验。采用SPSS22.0分析ALDH2基因rs671位点多态性及其他因素与CINV间的关系。

**结果:** 
多西他赛联合顺铂化疗方案首次化疗恶性肿瘤患者CINV发生率为48.9%；单因素分析显示ALDH2基因rs671位点多态性与CINV相关（P < 0.05）；Logistic回归分析显示rs671位点突变型（OR：3.019，95% CI：1.056~8.628，P < 0.05）、化疗前平均睡眠时间≤6 h（OR：2.807，95% CI：1.033~7.628，P < 0.05）是影响多西他赛联合顺铂化疗方案首次化疗恶性肿瘤患者CINV发生情况的相关因素。

**结论:** 
ALDH2基因rs671位点突变是影响CINV发生情况的相关因素，需进一步明确其内在影响机制，以更加精准、有效地管控临床CINV发生情况。

Keywords: 恶性肿瘤, 乙醛脱氢酶2, 单核苷酸多态性, 化疗所致恶心呕吐

### 目的

探寻乙醛脱氢酶2（ALDH2）基因rs671位点单核苷酸多态性与化疗所致恶心呕吐的相关性。

### 方法

选择恶性肿瘤首次住院化疗的90例中国患者，多时段观察收集三联止呕方案下患者接受多西他赛联合顺铂化疗方案后120 h内化疗所致恶心呕吐（CINV）的发生情况。问卷采集所有患者的年龄、性别、肿瘤分期、习惯性饮酒、晕动症史、孕吐史、化疗前平均睡眠时间等的资料，并对其ALDH2基因rs671位点进行基因型检测。利用效用程序计算遗传连锁分析Hardy-Weinberg平衡检验。采用SPSS22.0分析ALDH2基因rs671位点多态性及其他因素与CINV间的关系。

### 结果

多西他赛联合顺铂化疗方案首次化疗恶性肿瘤患者CINV发生率为48.9%；单因素分析显示ALDH2基因rs671位点多态性与CINV相关（*P* < 0.05）；Logistic回归分析显示rs671位点突变型（OR：3.019，95% *CI*：1.056~8.628，*P* < 0.05）、化疗前平均睡眠时间≤6 h（OR：2.807，95% *CI*：1.033~7.628，*P* < 0.05）是影响多西他赛联合顺铂化疗方案首次化疗恶性肿瘤患者CINV发生情况的相关因素。

### 结论

ALDH2基因rs671位点突变是影响CINV发生情况的相关因素，需进一步明确其内在影响机制，以更加精准、有效地管控临床CINV发生情况。

### Objective

To investigate the correlation between aldehyde dehydrogenase 2 (ALDH2) rs671 polymorphisms and chemotherapy-induced nausea and vomiting (CINV).

### Methods

A total of 90 Chinese patients with malignant tumors receiving chemotherapy for the first time were recruited in this study. The occurrence of CINV was observed within 120 h after treatment with docetaxel and cis-platinum chemotherapy (DP regimen). The data of the patients (including age, gender, tumor stage, habitual alcohol consumption, motion sickness, morning sickness, and average sleep time prior to chemotherapy) were collected through a questionnaire. ALDH2 rs671 polymorphisms of the patients were analyzed using a multiple single nucleotide polymorphism genotyping, and the Hardy-Weinberg equation was used for genetic linkage analysis. The correlations between the factors including ALDH2 rs671 polymorphisms and the occurrence of CINV were analyzed.

### Results

The incidence of CINV was 48.9% among the patients receiving their first chemotherapy with DP regimen. Univariate analysis indicated that the genetic polymorphisms of ALDH2 rs671 were significantly correlated with the occurrence of CINV (*P* < 0.05). Multivariate logistic analysis indicated that ALDH2 rs671 mutation (OR: 3.019, 95% *CI*: 1.056-8.628, *P* < 0.05) and average sleep time prior to chemotherapy no longer than 6 h (OR: 2.807, 95% *CI*: 1.033-7.628, *P* < 0.05) were risk factors for CINV in patients with malignant tumors receiving the first chemotherapy with DP regimen.

### Conclusion

ALDH2 gene mutation at rs671 is a risk factor contributing to the occurrence of CINV, and understanding of the underlying mechanism may help to more effectively control the occurrence of CINV.

## 1. 资料和方法

### 1.1. 一般资料

选取2022年于湘雅二医院肿瘤中心住院治疗的恶性肿瘤初治的中国患者作为研究对象。纳入标准：经病理学诊断为恶性肿瘤，年龄≥18周岁，纳入前未接受过肿瘤化学治疗；选取多西他赛联合顺铂高致呕性化疗方案（DP方案）行第1周期化疗，多西他赛第1天给药，顺铂连用3 d，顺铂每周期总量≥60 mg/m^2^；使用三联止呕方案，具体用量用法为：化疗第1天静脉注射帕洛诺司琼0.25 mg；化疗前1 d起至化疗结束（连续4 d），每日口服地塞米松8 mg；化疗第1天口服阿瑞匹坦125 mg，化疗第2、3天口服阿瑞匹坦80 mg。排除标准：合并消化道梗阻、前庭失调等导致恶心、呕吐原发病；合并严重的精神障碍类疾病；合并严重的心、肺、脑或其它器官功能障碍；沟通交流存在障碍、不能借助工具解除；治疗开始后出现严重骨髓抑制或肝肾功能异常，不能继续耐受化疗者。研究方案已通过中南大学湘雅二医院伦理委员会审批（批号：LYG2022111），患者对本研究内容、目的、配合要点等充分知情，自愿签署知情同意书。最终共纳入90例研究对象，年龄33~70（51.86±9.173）岁。化疗前均无恶心呕吐症状，均完成研究随访，各项资料收集完成率达100%。

### 1.2. 数据收集及评估

#### 1.2.1. 一般资料

包括年龄、性别及肿瘤分期，由研究者在患者入组当天从医院电子病历系统中收集，并于主治医生处核对无误后记录。

#### 1.2.2. 恶心呕吐发生情况

包括恶心或呕吐的发生时间及次数，由研究者从化疗当天开始收集，每天面对面问询研究对象，连续记录5 d。本研究将恶心界定为以反胃和/或急需呕吐为特征的疾病；将呕吐界定为胃内容物经口吐出的一种反射动作；将使用化疗药物0~24 h内出现的恶心或呕吐判定为急性CINV；将使用化疗药物24 h后出现的恶心或呕吐判定为延迟性CINV；将给予化疗药物后0~120 h内未使用解救性止吐药物且未出现恶心、呕吐判定为CINV完全缓解。恶心呕吐分级参照常见不良反应事件术语评定标准5.0版。本研究将化疗第1~5天内曾出现1级以上的恶心及/或呕吐判定为CINV发生；CINV发生程度以第1~5天中出现的最高级别为准。

#### 1.2.3. 其他资料

包括习惯性饮酒、晕动症史、孕吐史、化疗前平均睡眠时间，指标选取参照相关研究^[2, 4-6, 8, 16]^。本研究将经常性饮酒界定为有饮酒史，即每周至少1次饮酒，连续或累计6月及以上^[11, 17]^；晕动症界定为乘坐汽车、轮船或者飞机时常有恶心、面色苍白、出冷汗、唾液分泌增多和/或呕吐反应；孕吐界定为女性孕早期有厌食、恶心、呕吐等症状。化疗前平均睡眠时间指研究对象实施化疗当日往前推算3 d的平均睡眠时间（精确到小时）。此部分所有指标由研究者于化疗第1天使用化疗药物前，借助问卷以面对面问询、自我报告的方式采集。

### 1.3. 基因型分析

#### 1.3.1. 样本采集及保存

化疗前采用EDTA抗凝管抽取研究对象外周静脉血3 mL，采血后轻轻颠倒10次，室温1200×*g*离心10 min，将白细胞层提取到冻存管，并放入-80 ℃冰箱保存，待后续集中检测。

#### 1.3.2. ALDH2基因rs671位点多态性分析

采用SNPscan^TM^分型试剂盒（上海天昊生物科技有限公司）分析rs671位点多态性。使用分型检测准确性及成功率更高的多重SNP分型技术-iMLDR^®^多重SNP分型技术来检测ALDH2基因rs671位点多态性。通过扩增含有目标SNP位点的DNA片段[PCR引物：F-seq(5'-3'): TGGCTACAAGATGTCGGGGAGT；R-seq(5'-3'): AT CCCCAGCAGGTCCTGA-ACTT]，使用外切核酸酶及虾碱酶纯化扩增产物并以此为后续连接酶模版。连接反应中，连接引物包括：（1）rs671FA (Seq5'-3': TA CGGTTATTCGGGC-TCCTGTACGGGCTGCAGGC ATACAGTA)；（2）rs671FG (Seq5'-3': TTCCGCG-TTC GGACTGATATACGGGCTGCAGGCATACAGTG)；（3）rs671FP (Seq5'-3': AAGTGAA AACTGTGAGTGT GGGACCTTTT)。每个位点包含2个5'端等位基因特异探针以及紧挨其后的一条3'端位点的荧光标记的特异探针，通过ABI3730XL基因测序仪的毛细管电泳来区分连接产物，最后采用GeneMapper4.1软件（Applied-biosystems, USA）来分析ABI3730XL测序仪上收集的原始数据。当rs671多态性位点检测为GG时，判定为ALDH2野生型（ALDH2^*^1/^*^1）；当为GA时判定为突变杂合型（ALDH2^*^1/^*^2）；当为AA时判定为突变纯合型（ALDH2^*^2/^*^2）。

### 1.4. 统计学分析

利用效用程序对rs671位点基因型行Hardy-Weinberg平衡检验。采用SPSS22.0对数据进行统计分析。对前述采集各变量与CINV关系单因素分析行卡方检验；多因素分析在应用共线性分析剔除共线性变量的基础上采用Logistic回归分析（α_入_=0.05，α_出_=0.10）。以*P* < 0.05为差异有统计学意义。

## 2. 结果

### 2.1. CINV间单因素分析

癌种分布：鼻咽癌51例、舌癌10例、颊癌5例、宫颈癌5例、喉癌4例、下咽癌4例、牙龈癌3例、口底癌2例、腮腺癌2例、颈部鳞状细胞癌1例、颌下腺癌1例、上颚癌1例、外阴癌1例。所有研究对象中CINV发生44例（48.9%），急性CINV发生13例（14.4%）、延迟性CINV发生43例（47.8%）。将各临床资料与CINV进行单因素分析，结果显示性别、晕动症史、孕吐史、习惯性饮酒、化疗前平均睡眠时间与CINV的发生具有关联（*P* < 0.05），应纳入多因素分析进一步明确变量间关系（[表 1](#Table1)、[图 1](#Figure1)）。

### 表 1.

| Characteristic | Respondent profile | CINV | Non-CINV | OR | χ2 | P |
| --- | --- | --- | --- | --- | --- | --- |
| Age (year) |   |   |   |   |   |   |
| < 50 | 40(44.4) | 20 (50.0) | 20 (50.0) | 0.923 | 0.036 | 0.850 |
| > 50 | 50 (55.6) | 24 (48.0) | 26 (52.0) |   |   |   |
| Gender |   |   |   |   |   |   |
| Female | 30 (33.3) | 21 (70.0) | 9 (30.0) | 3.754 | 8.026 | 0.005 |
| Male | 60 (66.7) | 23 (38.3) | 37(61.7) |   |   |   |
| Motion sickness |   |   |   |   |   |   |
| Yes | 27 (30.0) | 20(74.1) | 7 (25.9) | 4.643 | 9.791 | 0.002 |
| No | 63 (70.0) | 24 (38.1) | 39(61.9) |   |   |   |
| Morning sicknessa |   |   |   |   |   |   |
| Yes | 19(63.3) | 17 (89.5) | 2 (10.5) | 14.875 | - | 0.004b |
| No | 11(36.7) | 4 (36.4) | 7 (63.6) |   |   |   |
| Habitual consumption of alcohol |   |   |   |   |   |   |
| No | 40 (44.4) | 25 (62.5) | 15 (37.5) | 2.717 | 5.338 | 0.021 |
| Yes | 50 (55.6) | 19 (38.0) | 31 (62.0) |   |   |   |
| Average sleep time prior to chemotherapy (h) |   |   |   |   |   |   |
| < 6 | 32 (35.6) | 21 (65.6) | 11 (34.4) | 2.905 | 5.566 | 0.018 |
| > 6 | 58 (64.4) | 23 (39.7) | 35 (60.3) |   |   |   |
| Clinical stage of tumor |   |   |   |   |   |   |
| Ⅰ/Ⅱ/Ⅲ | 47 (52.2) | 25 (53.2) | 22 (46.8) | 0.697 | 0.729 | 0.393 |
| Ⅳ | 43 (47.8) | 19 (44.2) | 24 (55.8) |   |   |   |

Table Caption: 临床资料与CINV间单因素分析 Univariate analysis of the demographic and clinical data of the cancer patients with and without chemotherapyinduced nausea and vomiting (CINV) [n(%)]

### 图 1.

![图 1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd7/10339303/36b98bd3bf02/nfykdxxb-43-6-1017-1.jpg)

CINV风险预测因素 Risk predictors of CINV, including ALDH2 rs671 (GA & AA vs GG); Average sleep time prior to chemotherapy(≤6 h vs >6 h); Habitual consumption of alcohol (No vs Yes); Morning sickness (Yes vs No); Motion sickness (Yes vs No); and gender (Female vs Male).

### 2.2. ALDH2基因rs671位点多态性与习惯性饮酒间单因素分析

ALDH2基因rs671位点多态性与习惯性饮酒间单因素分析结果显示：rs671位点突变型较之野生型，习惯性饮酒者占比更少（OR=0.388，95%*CI*：0.160~0.942，*P* < 0.05，[表 2](#Table2)）。这与研究设计假设“习惯性饮酒的患者CINV发生风险低可能与ALDH2基因型有关”指示方向一致，可进一步分析ALDH2基因rs671位点多态性与CINV间关系。

### 表 2.

| Frequent alcohol consumption | GG group [n(%)] | GA & AA group [n(%)] | χ2 | OR | 95% CI | P |
| --- | --- | --- | --- | --- | --- | --- |
| Yes | 37 (63.79) | 13 (40.62) | 4.483 | 0.388 | 0.160-0.942 | 0.034 |
| No | 21 (39.21) | 19 (59.38) |  |  |  |  |

Table Caption: ALDH2基因rs671位点多态性与习惯性饮酒间单因素分析 Univariate analysis betweenALDH2 rs671 polymorphisms and frequent alcohol consumption

### 2.3. ALDH2基因rs671位点多态性与CINV间单因素分析

ALDH2基因rs671位点多态性分布符合Hardy-Weinberg平衡（χ^2^=0.073，*P*=0.786），具有遗传代表性，可进行基因分析。本组研究对象ALDH2基因rs671位点野生型（GG）、突变杂合型（GA）、突变纯合型（AA）分别为58例（64.44%）、29例（32.22%）、3例（3.33%）。将突变杂合型、突变纯合型统称为突变型，则rs671位点突变型32例（35.56%）、野生型58例（64.4%）。分析使用DP方案后CINV的发生情况，结果显示：rs671位点突变型延迟性CINV发生率、总CINV发生率均高于野生型（*P* < 0.05）。rs671位点突变型相比野生型延迟性CINV的发生率有所增加（OR=2.536，95% *CI*：1.043~6.165，*P* < 0.05）；rs671位点突变型相比野生型总CINV发生率有所增加（OR=2.905，95% *CI*：1.182~7.141，*P* < 0.05）。rs671位点突变型与野生型两者在急性CINV发生率的差异无统计学意义（*P*>0.05）。发生CINV的患者中，rs671位点野生型与突变型间在CINV分级上的表现差异无统计学意义（*P*>0.05，[表 3](#Table3)）。

### 表 3.

| Occurrence of CINV | GG group [n(%)] | GA & AA group [n(%)] | χ2/Z | OR | 95% CI | P |
| --- | --- | --- | --- | --- | --- | --- |
| CINV types |   |   |   |   |   |   |
| Delayed CINV | 23 (29.3) | 20 (62.5) | 4.314 | 2.536 | 1.043-6.165 | 0.038 |
| Acute CINV | 6 (10.3) | 7(21.9) | 2.218 | 2.427 | 0.738-7.978 | 0.136 |
| Total CINV | 23 (39.7) | 21 (65.6) | 5.566 | 2.905 | 1.182-7.141 | 0.018 |
| CINV grades |   |   |   |   |   |   |
| Grade 1 | 8 (34.8) | 10 (47.6) | -0.913 | - |   | 0.361 |
| Grade 2 | 10(43.5) | 8 (38.1) |   |   |   |   |
| Grade 3 | 5 (21.7) | 3 (14.3) |   |   |   |   |

Table Caption: ALDH2基因rs671位点多态性与CINV发生情况间的单因素分析 Univariate analysis betweenALDH2 rs671 polymorphisms and the occurrence of CINV

### 2.4. 临床资料及ALDH2基因rs671位点多态性与CINV间多因素分析

将单因素分析筛查有统计学意义临床变量：性别、晕动症史、化疗前平均睡眠时间、习惯性饮酒及ALDH2基因rs671位点多态性纳入CINV发生与否的多因素Logistic回归方程分析（因本组仅纳入女性患者30例，暂未纳入孕吐史进行方程回归分析），结果显示rs671位点突变（OR: 3.019，95% *CI*: 1.056~8.628，*P* < 0.05）、化疗前平均睡眠时间≤6 h（OR: 2.807，95% *CI*: 1.033~7.628]，*P* < 0.05）是CINV是否发生的危险因素（[表 4](#Table4)）。

### 表 4.

| Factors | B | S.E. | Wald | P | OR | 95% CI |
| --- | --- | --- | --- | --- | --- | --- |
| ALDH2 rs671 | 1.105 | 0.536 | 4.251 | 0.039 | 3.019 | 1.056-8.628 |
| Average sleep time prior to chemotherapy | 1.032 | 0.510 | 4.096 | 0.043 | 2.807 | 1.033-7.628 |
| Gender | 0.902 | 0.694 | 1.688 | 0.194 | 2.463 | 0.632-9.600 |
| Motion sickness | 0.816 | 0.643 | 1.611 | 0.204 | 2.263 | 0.641-7.982 |
| Frequent alcohol consumption | 0.303 | 0.557 | 0.296 | 0.586 | 1.354 | 0.454-4.039 |

Table Caption: CINV风险预测因素的Logistic回归分析 Logistic analysis of risk factors for CINV

## 3. 讨论

本组研究对象均为采用DP高致吐化疗方案行首次化疗的恶性肿瘤患者，根据药物致吐潜能予以指南推荐的三联止呕方案^[5, 6]^后连续观测5 d，发现患者中CINV发生率仍高达48.9%，这与既往研究结果类似^[11, 16]^。对于采用DP高致吐化疗方案的患者，即使临床使用“三联”止呕方案，仍有近半数患者会经历化疗所带来的不同程度的恶心、呕吐不适感受（其中1、2、3级恶心呕吐分别占比40.91%、40.91%、18.18%），距离实现CINV完全缓解终极目标仍有较大空间，CINV临床管理成效仍有待提升^[7]^，仅根据化疗药物客观致吐性制定及实施止呕方案未必就是临床最佳选择。

随着全基因组关联分析研究的进展，SNP作为最常见、最简单的一类可遗传稳定变异，已作为疾病严重性和疾病状态的潜在生物标志受到了越来越多的关注^[13, 18-20]^。在癌症治疗管理领域，SNP虽已在基因诊断、靶向治疗方面大放异彩，但作为客观生物标志物在疾病症状管理方面仍处研究起步阶段^[13]^，基因多态性与癌症症状管理、治疗不良反应间的关系尚待不断深入。CINV是肿瘤化学治疗最常见的不良反应，同时也是威胁肿瘤患者治疗依从性的最为重要的危险因素之一，占据着肿瘤治疗相关症状管理的重要地位。

现有CINV管理相关研究发现：（1）习惯性饮酒是CINV发生的保护性因素，但具体机制尚不明确^[4-6, 11, 17]^；（2）ALDH2基因rs671位点基因多态性会影响ALDH2活性^[21]^；（3）ALDH2是乙醇代谢产物乙醛氧化解毒的关键限速酶，可影响饮酒行为^[21, 22]^；（4）不同种族和地区人群ALDH2基因型及酶活性存在明显差异^[23-25]^：ALDH2基因rs671位点突变率在非洲和欧美人群中仅为10%左右^[26]^，而在亚洲人群中则高达40%^[24]^；（5）欧美地区化疗患者CINV发生率及严重程度低于亚洲地区^[27]^。综合以上，本研究合理假设习惯性饮酒的患者CINV发生风险低可能与ALDH2基因型及ALDH2活性有关。本研究设计初步探讨CINV与ALDH2基因多态性的相关性，除纳入与既往研究^[2, 4-6, 11, 15, 16, 20]^相似的个体因素（年龄、性别、肿瘤分期、习惯性饮酒、晕动症史、孕吐史、化疗前平均睡眠时间）外，受临床经验及基础实验^[4-6, 13, 14, 21, 28-30]^启发，还将ALDH2基因rs671位点多态性纳入CINV风险因素筛选、进行CINV风险概率预测，以期更精准地预测CINV事件发生可能性，从而协助临床人员制定个性化的CINV“防治护”方案，更加精准有效管理CINV。

本研究结果单因素分析部分再次印证了与既往研究^[2, 4-6, 13-16, 20]^相似的众多影响因素，还发现了ALDH2基因rs671位点野生型与突变型患者CINV发生率的差异有统计学意义（39.7% *vs* 65.6%，χ^2^=5.566，*P* < 0.05），当将患者按ALDH2基因rs671位点多态性进行分组时，也发现野生型患者中有习惯性饮酒者所占比例更高（χ^2^=4.483，*P*=0.034），这与既往研究^[15]^相符合；但在发生CINV的患者中，rs671位点野生型和突变型两组患者间在CINV分级上的差异尚无统计学意义（*P*>0.05），这也有待进一步分析验证。Logistic回归分析也发现，在控制其他因素不变的基础上，rs671位点的突变会使得CINV发生风险提升（OR=3.019, *P* < 0.05），rs671位点突变是CINV的相关影响因素（*P* < 0.05）。至此，本研究认为有必要进一步更新“CINV风险预测因子库”，将基因多态性引入CINV风险评估领域的相关研究，为化疗前预测CINV发生风险提供更为稳定、客观、量化的指标，而ALDH2基因rs671位点极有可能占据重要的一席之地，这也有待进一步的机制研究分析确认。考虑ALDH2基因型的检测操作过程并不复杂，不需要花费过多的人力、物力，检测费用实惠，若将ALDH2基因型检测应用于癌症化疗前常规检测，研发出相关途径作用药物，对于实现CINV精准预测、科学防治护措施制定也有着重要意义。

本研究尚存在一定的局限性及不足：研究对象为单中心入组、样本数量有限，考虑到不同种族和地区人群ALDH2基因型变异可能，研究结果的科学、普适性有待进一步验证；研究对象纳入瘤种未作区分，未包含消化道肿瘤，化疗用药剂量不统一，有待进一步补充扩大研究样本量，细化瘤种、方案及用药剂量进行分层分析，进一步分析验证研究结果的可推广性；方案为单一治疗方案的首次化疗患者，研究对象的多样性有待补充；ALDH2基因多态性影响CINV的作用途径及内在机制尚不清楚，有待进一步补充ALDH2活性检测及其与ALDH2基因突变、CINV发生等关联检测，以更加有力、科学地验证研究结果，指导临床。

综上，本研究结果认为rs671位点突变、化疗前平均睡眠时间不足6 h是影响首次行DP高致吐化疗方案患者CINV的相关因素，为从遗传角度探究CINV等癌症症状管理提供了新视野及思路。

## Biography

杨群，硕士，副主任护师，护士长，E-mail: yangqun1977@csu.edu.cn

## Funding Statement

湖南省自然科学基金（2020JJ4821，2021JJ40816）

## Contributor Information

杨 群 (Qun YANG), Email: yangqun1977@csu.edu.cn.

刘 晓鑫 (Xiaoxin LIU), Email: liuxiaoxin0424@csu.edu.cn.

## References

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CACancer J Clin. 2021;71(3):209–49. doi: 10.3322/caac.21660.  [DOI](https://doi.org/10.3322/caac.21660) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/33538338/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=CACancer%20J%20Clin&title=Global%20cancer%20statistics%202020:%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries&author=H%20Sung&author=J%20Ferlay&author=RL%20Siegel&volume=71&issue=3&publication_year=2021&pages=209-49&pmid=33538338&doi=10.3322/caac.21660&)

2. Sommariva S, Pongiglione B, Tarricone R. Impact of chemotherapyinduced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit Rev Oncol. 2016;99:13–36. doi: 10.1016/j.critrevonc.2015.12.001.  [DOI](https://doi.org/10.1016/j.critrevonc.2015.12.001) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/26697988/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Crit%20Rev%20Oncol&title=Impact%20of%20chemotherapyinduced%20nausea%20and%20vomiting%20on%20health-related%20quality%20of%20life%20and%20resource%20utilization:%20a%20systematic%20review&author=S%20Sommariva&author=B%20Pongiglione&author=R%20Tarricone&volume=99&publication_year=2016&pages=13-36&pmid=26697988&doi=10.1016/j.critrevonc.2015.12.001&)

3. Razvi Y, Chan S, McFarlane T, et al. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer. 2019;27(1):87–95. doi: 10.1007/s00520-018-4464-y.  [DOI](https://doi.org/10.1007/s00520-018-4464-y) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/30284039/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Support%20Care%20Cancer&title=ASCO,%20NCCN,%20MASCC/ESMO:%20a%20comparison%20of%20antiemetic%20guidelines%20for%20the%20treatment%20of%20chemotherapy-induced%20nausea%20and%20vomiting%20in%20adult%20patients&author=Y%20Razvi&author=S%20Chan&author=T%20McFarlane&volume=27&issue=1&publication_year=2019&pages=87-95&pmid=30284039&doi=10.1007/s00520-018-4464-y&)

4. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782–97. doi: 10.1200/JCO.20.01296.  [DOI](https://doi.org/10.1200/JCO.20.01296) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/32658626/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&title=Antiemetics:%20ASCO%20guideline%20update&author=PJ%20Hesketh&author=MG%20Kris&author=E%20Basch&volume=38&issue=24&publication_year=2020&pages=2782-97&pmid=32658626&doi=10.1200/JCO.20.01296&)

5. Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329–59. doi: 10.6004/jnccn.2021.0012.  [DOI](https://doi.org/10.6004/jnccn.2021.0012) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/33724754/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Natl%20Compr%20Canc%20Netw&title=Colon%20cancer,%20version%202.2021,%20NCCN%20clinical%20practice%20guidelines%20in%20oncology&author=AB%20Benson&author=AP%20Venook&author=MM%20Al-Hawary&volume=19&issue=3&publication_year=2021&pages=329-59&pmid=33724754&doi=10.6004/jnccn.2021.0012&)

6. 上海市抗癌协会癌症康复与姑息专业委员会 化疗所致恶心呕吐全程管理上海专家共识(2018年版) 中国癌症杂志. 2018;28(12):946–60.  [Google Scholar](https://scholar.google.com/scholar_lookup?journal=%E4%B8%AD%E5%9B%BD%E7%99%8C%E7%97%87%E6%9D%82%E5%BF%97&title=%E5%8C%96%E7%96%97%E6%89%80%E8%87%B4%E6%81%B6%E5%BF%83%E5%91%95%E5%90%90%E5%85%A8%E7%A8%8B%E7%AE%A1%E7%90%86%E4%B8%8A%E6%B5%B7%E4%B8%93%E5%AE%B6%E5%85%B1%E8%AF%86(2018%E5%B9%B4%E7%89%88)&author=%20%E4%B8%8A%E6%B5%B7%E5%B8%82%E6%8A%97%E7%99%8C%E5%8D%8F%E4%BC%9A%E7%99%8C%E7%97%87%E5%BA%B7%E5%A4%8D%E4%B8%8E%E5%A7%91%E6%81%AF%E4%B8%93%E4%B8%9A%E5%A7%94%E5%91%98%E4%BC%9A&volume=28&issue=12&publication_year=2018&pages=946-60&)

7. Aapro M, Caprariu Z, Chilingirov P, et al. Assessing the impact of antiemetic guideline compliance on prevention of chemotherapyinduced nausea and vomiting: results of the nausea/emesis registry in oncology (NERO) Eur J Cancer. 2022;166:126–33. doi: 10.1016/j.ejca.2022.01.028.  [DOI](https://doi.org/10.1016/j.ejca.2022.01.028) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/35290913/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Cancer&title=Assessing%20the%20impact%20of%20antiemetic%20guideline%20compliance%20on%20prevention%20of%20chemotherapyinduced%20nausea%20and%20vomiting:%20results%20of%20the%20nausea/emesis%20registry%20in%20oncology%20(NERO)&author=M%20Aapro&author=Z%20Caprariu&author=P%20Chilingirov&volume=166&publication_year=2022&pages=126-33&pmid=35290913&doi=10.1016/j.ejca.2022.01.028&)

8. 毛 咏旻, 王 一红, 谢 腾, et al. 中西医防治顺铂引起化疗后恶心呕吐反应的研究进展. 中华全科医学. 2017;15(2):321–4.  [Google Scholar](https://scholar.google.com/scholar_lookup?journal=%E4%B8%AD%E5%8D%8E%E5%85%A8%E7%A7%91%E5%8C%BB%E5%AD%A6&title=%E4%B8%AD%E8%A5%BF%E5%8C%BB%E9%98%B2%E6%B2%BB%E9%A1%BA%E9%93%82%E5%BC%95%E8%B5%B7%E5%8C%96%E7%96%97%E5%90%8E%E6%81%B6%E5%BF%83%E5%91%95%E5%90%90%E5%8F%8D%E5%BA%94%E7%9A%84%E7%A0%94%E7%A9%B6%E8%BF%9B%E5%B1%95&author=%E5%92%8F%E6%97%BB%20%E6%AF%9B&author=%E4%B8%80%E7%BA%A2%20%E7%8E%8B&author=%E8%85%BE%20%E8%B0%A2&volume=15&issue=2&publication_year=2017&pages=321-4&)

9. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482–94. doi: 10.1056/NEJMra0706547.  [DOI](https://doi.org/10.1056/NEJMra0706547) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/18525044/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Chemotherapy-induced%20nausea%20and%20vomiting&author=PJ%20Hesketh&volume=358&issue=23&publication_year=2008&pages=2482-94&pmid=18525044&doi=10.1056/NEJMra0706547&)

10. Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapyinduced nausea and vomiting. N Engl J Med. 2016;374(14):1356–67. doi: 10.1056/NEJMra1515442.  [DOI](https://doi.org/10.1056/NEJMra1515442) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/27050207/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Antiemetic%20prophylaxis%20for%20chemotherapyinduced%20nausea%20and%20vomiting&author=RM%20Navari&author=M%20Aapro&volume=374&issue=14&publication_year=2016&pages=1356-67&pmid=27050207&doi=10.1056/NEJMra1515442&)

11. 曹 众平, 熊 习安, 杨 群. 朴素贝叶斯分类器在化疗所致恶心呕吐风险预测模型上的应用. 南方医科大学学报. 2021;41(4):607–12. doi: 10.12122/j.issn.1673-4254.2021.04.19.  [DOI](https://doi.org/10.12122/j.issn.1673-4254.2021.04.19) | [PMC free article](/articles/PMC8110439/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/33963723/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=%E5%8D%97%E6%96%B9%E5%8C%BB%E7%A7%91%E5%A4%A7%E5%AD%A6%E5%AD%A6%E6%8A%A5&title=%E6%9C%B4%E7%B4%A0%E8%B4%9D%E5%8F%B6%E6%96%AF%E5%88%86%E7%B1%BB%E5%99%A8%E5%9C%A8%E5%8C%96%E7%96%97%E6%89%80%E8%87%B4%E6%81%B6%E5%BF%83%E5%91%95%E5%90%90%E9%A3%8E%E9%99%A9%E9%A2%84%E6%B5%8B%E6%A8%A1%E5%9E%8B%E4%B8%8A%E7%9A%84%E5%BA%94%E7%94%A8&author=%E4%BC%97%E5%B9%B3%20%E6%9B%B9&author=%E4%B9%A0%E5%AE%89%20%E7%86%8A&author=%E7%BE%A4%20%E6%9D%A8&volume=41&issue=4&publication_year=2021&pages=607-12&pmid=33963723&doi=10.12122/j.issn.1673-4254.2021.04.19&)

12. Pan M, Li DZ. Single nucleotide polymorphism-based cell-free DNA prenatal screening for 22q11.2 deletion syndrome. Am J Obstet Gynecol. 2022;227(1):123–4. doi: 10.1016/j.ajog.2022.01.034.  [DOI](https://doi.org/10.1016/j.ajog.2022.01.034) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/35122717/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am%20J%20Obstet%20Gynecol&title=Single%20nucleotide%20polymorphism-based%20cell-free%20DNA%20prenatal%20screening%20for%2022q11.2%20deletion%20syndrome&author=M%20Pan&author=DZ%20Li&volume=227&issue=1&publication_year=2022&pages=123-4&pmid=35122717&doi=10.1016/j.ajog.2022.01.034&)

13. 林 栋美, 孟 利敏, 尹 西西, et al. 癌症症状群生物学标志物研究进展. 赣南医学院学报. 2019;39(11):1109–13.  [Google Scholar](https://scholar.google.com/scholar_lookup?journal=%E8%B5%A3%E5%8D%97%E5%8C%BB%E5%AD%A6%E9%99%A2%E5%AD%A6%E6%8A%A5&title=%E7%99%8C%E7%97%87%E7%97%87%E7%8A%B6%E7%BE%A4%E7%94%9F%E7%89%A9%E5%AD%A6%E6%A0%87%E5%BF%97%E7%89%A9%E7%A0%94%E7%A9%B6%E8%BF%9B%E5%B1%95&author=%E6%A0%8B%E7%BE%8E%20%E6%9E%97&author=%E5%88%A9%E6%95%8F%20%E5%AD%9F&author=%E8%A5%BF%E8%A5%BF%20%E5%B0%B9&volume=39&issue=11&publication_year=2019&pages=1109-13&)

14. Uomori T, Horimoto Y, Mogushi K, et al. Relationship between alcohol metabolism and chemotherapy-induced emetic events in breast cancer patients. Breast Cancer. 2017;24(5):702–7. doi: 10.1007/s12282-017-0761-4.  [DOI](https://doi.org/10.1007/s12282-017-0761-4) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/28217830/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Breast%20Cancer&title=Relationship%20between%20alcohol%20metabolism%20and%20chemotherapy-induced%20emetic%20events%20in%20breast%20cancer%20patients&author=T%20Uomori&author=Y%20Horimoto&author=K%20Mogushi&volume=24&issue=5&publication_year=2017&pages=702-7&pmid=28217830&doi=10.1007/s12282-017-0761-4&)

15. Edenberg HJ, McClintick JN. Alcohol dehydrogenases, aldehyde dehydrogenases, and alcohol use disorders: a critical review. Alcohol Clin Exp Res. 2018;42(12):2281–97. doi: 10.1111/acer.13904.  [DOI](https://doi.org/10.1111/acer.13904) | [PMC free article](/articles/PMC6286250/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/30320893/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Alcohol%20Clin%20Exp%20Res&title=Alcohol%20dehydrogenases,%20aldehyde%20dehydrogenases,%20and%20alcohol%20use%20disorders:%20a%20critical%20review&author=HJ%20Edenberg&author=JN%20McClintick&volume=42&issue=12&publication_year=2018&pages=2281-97&pmid=30320893&doi=10.1111/acer.13904&)

16. Clemons M. Guidelines versus individualized care for the management of CINV. Support Care Cancer. 2018;26(1):11–7. doi: 10.1007/s00520-018-4115-3.  [DOI](https://doi.org/10.1007/s00520-018-4115-3) | [PMC free article](/articles/PMC5876263/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/29556809/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Support%20Care%20Cancer&title=Guidelines%20versus%20individualized%20care%20for%20the%20management%20of%20CINV&author=M%20Clemons&volume=26&issue=1&publication_year=2018&pages=11-7&pmid=29556809&doi=10.1007/s00520-018-4115-3&)

17. 邓 本敏, 陈 月梅, 边 志衡, et al. 化疗相关性恶心和呕吐风险预测模型的构建. 中国护理管理. 2022;22(9):1384–90.  [Google Scholar](https://scholar.google.com/scholar_lookup?journal=%E4%B8%AD%E5%9B%BD%E6%8A%A4%E7%90%86%E7%AE%A1%E7%90%86&title=%E5%8C%96%E7%96%97%E7%9B%B8%E5%85%B3%E6%80%A7%E6%81%B6%E5%BF%83%E5%92%8C%E5%91%95%E5%90%90%E9%A3%8E%E9%99%A9%E9%A2%84%E6%B5%8B%E6%A8%A1%E5%9E%8B%E7%9A%84%E6%9E%84%E5%BB%BA&author=%E6%9C%AC%E6%95%8F%20%E9%82%93&author=%E6%9C%88%E6%A2%85%20%E9%99%88&author=%E5%BF%97%E8%A1%A1%20%E8%BE%B9&volume=22&issue=9&publication_year=2022&pages=1384-90&)

18. 田 艳君, 刘 传新, 刘 海青, et al. 抑郁症全基因组关联分析的研究进展. 中华诊断学电子杂志. 2017;5(2):140–3.  [Google Scholar](https://scholar.google.com/scholar_lookup?journal=%E4%B8%AD%E5%8D%8E%E8%AF%8A%E6%96%AD%E5%AD%A6%E7%94%B5%E5%AD%90%E6%9D%82%E5%BF%97&title=%E6%8A%91%E9%83%81%E7%97%87%E5%85%A8%E5%9F%BA%E5%9B%A0%E7%BB%84%E5%85%B3%E8%81%94%E5%88%86%E6%9E%90%E7%9A%84%E7%A0%94%E7%A9%B6%E8%BF%9B%E5%B1%95&author=%E8%89%B3%E5%90%9B%20%E7%94%B0&author=%E4%BC%A0%E6%96%B0%20%E5%88%98&author=%E6%B5%B7%E9%9D%92%20%E5%88%98&volume=5&issue=2&publication_year=2017&pages=140-3&)

19. 凃 欣, 石 立松, 汪 樊, et al. 全基因组关联分析的进展与反思. 生理科学进展. 2010;41(2):87–94.  [PubMed](https://pubmed.ncbi.nlm.nih.gov/21416992/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=%E7%94%9F%E7%90%86%E7%A7%91%E5%AD%A6%E8%BF%9B%E5%B1%95&title=%E5%85%A8%E5%9F%BA%E5%9B%A0%E7%BB%84%E5%85%B3%E8%81%94%E5%88%86%E6%9E%90%E7%9A%84%E8%BF%9B%E5%B1%95%E4%B8%8E%E5%8F%8D%E6%80%9D&author=%E6%AC%A3%20%E5%87%83&author=%E7%AB%8B%E6%9D%BE%20%E7%9F%B3&author=%E6%A8%8A%20%E6%B1%AA&volume=41&issue=2&publication_year=2010&pages=87-94&pmid=21416992&)

20. 王 子贤, 赖 伟华, 钟 诗龙. 两样本孟德尔随机化方法分析血液代谢物与冠心病的因果关系. 南方医科大学学报. 2021;41(2):272–8. doi: 10.12122/j.issn.1673-4254.2021.02.16.  [DOI](https://doi.org/10.12122/j.issn.1673-4254.2021.02.16) | [PMC free article](/articles/PMC7905253/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/33624602/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=%E5%8D%97%E6%96%B9%E5%8C%BB%E7%A7%91%E5%A4%A7%E5%AD%A6%E5%AD%A6%E6%8A%A5&title=%E4%B8%A4%E6%A0%B7%E6%9C%AC%E5%AD%9F%E5%BE%B7%E5%B0%94%E9%9A%8F%E6%9C%BA%E5%8C%96%E6%96%B9%E6%B3%95%E5%88%86%E6%9E%90%E8%A1%80%E6%B6%B2%E4%BB%A3%E8%B0%A2%E7%89%A9%E4%B8%8E%E5%86%A0%E5%BF%83%E7%97%85%E7%9A%84%E5%9B%A0%E6%9E%9C%E5%85%B3%E7%B3%BB&author=%E5%AD%90%E8%B4%A4%20%E7%8E%8B&author=%E4%BC%9F%E5%8D%8E%20%E8%B5%96&author=%E8%AF%97%E9%BE%99%20%E9%92%9F&volume=41&issue=2&publication_year=2021&pages=272-8&pmid=33624602&doi=10.12122/j.issn.1673-4254.2021.02.16&)

21. Li DW, Zhao HY, Gelernter J. Strong protective effect of the aldehyde dehydrogenase gene (ALDH2) 504lys (*2) allele against alcoholism and alcohol-induced medical diseases in Asians. Hum Genet. 2012;131(5):725–37. doi: 10.1007/s00439-011-1116-4.  [DOI](https://doi.org/10.1007/s00439-011-1116-4) | [PMC free article](/articles/PMC3548401/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/22102315/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Hum%20Genet&title=Strong%20protective%20effect%20of%20the%20aldehyde%20dehydrogenase%20gene%20(ALDH2)%20504lys%20(*2)%20allele%20against%20alcoholism%20and%20alcohol-induced%20medical%20diseases%20in%20Asians&author=DW%20Li&author=HY%20Zhao&author=J%20Gelernter&volume=131&issue=5&publication_year=2012&pages=725-37&pmid=22102315&doi=10.1007/s00439-011-1116-4&)

22. 徐 斌, 罗 晓, 张 红, et al. ALDH2、ADH1B基因多态性在不同民族酒依赖者中的差异及其与饮酒行为的关系. 中国药物依赖性杂志. 2021;30(5):358–64.  [Google Scholar](https://scholar.google.com/scholar_lookup?journal=%E4%B8%AD%E5%9B%BD%E8%8D%AF%E7%89%A9%E4%BE%9D%E8%B5%96%E6%80%A7%E6%9D%82%E5%BF%97&title=ALDH2%E3%80%81ADH1B%E5%9F%BA%E5%9B%A0%E5%A4%9A%E6%80%81%E6%80%A7%E5%9C%A8%E4%B8%8D%E5%90%8C%E6%B0%91%E6%97%8F%E9%85%92%E4%BE%9D%E8%B5%96%E8%80%85%E4%B8%AD%E7%9A%84%E5%B7%AE%E5%BC%82%E5%8F%8A%E5%85%B6%E4%B8%8E%E9%A5%AE%E9%85%92%E8%A1%8C%E4%B8%BA%E7%9A%84%E5%85%B3%E7%B3%BB&author=%E6%96%8C%20%E5%BE%90&author=%E6%99%93%20%E7%BD%97&author=%E7%BA%A2%20%E5%BC%A0&volume=30&issue=5&publication_year=2021&pages=358-64&)

23. Greenberg DR, Bhambhvani HP, Basran SS, et al. ALDH2 expression, alcohol intake and Semen parameters among East Asian men. J Urol. 2022;208(2):406–13. doi: 10.1097/JU.0000000000002682.  [DOI](https://doi.org/10.1097/JU.0000000000002682) | [PMC free article](/articles/PMC9283262/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/35344413/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Urol&title=ALDH2%20expression,%20alcohol%20intake%20and%20Semen%20parameters%20among%20East%20Asian%20men&author=DR%20Greenberg&author=HP%20Bhambhvani&author=SS%20Basran&volume=208&issue=2&publication_year=2022&pages=406-13&pmid=35344413&doi=10.1097/JU.0000000000002682&)

24. 姜育燊. 中国人群乙醛脱氢酶2基因多态性性别与地域分布研究[C]. 第一届中国临床分子诊断大会论文集, 2018.

25. Zhang H, Fu L. The role of ALDH2 in tumorigenesis and tumor progression: targeting ALDH2 as a potential cancer treatment. Acta Pharm Sin B. 2021;11(6):1400–11. doi: 10.1016/j.apsb.2021.02.008.  [DOI](https://doi.org/10.1016/j.apsb.2021.02.008) | [PMC free article](/articles/PMC8245805/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/34221859/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Acta%20Pharm%20Sin%20B&title=The%20role%20of%20ALDH2%20in%20tumorigenesis%20and%20tumor%20progression:%20targeting%20ALDH2%20as%20a%20potential%20cancer%20treatment&author=H%20Zhang&author=L%20Fu&volume=11&issue=6&publication_year=2021&pages=1400-11&pmid=34221859&doi=10.1016/j.apsb.2021.02.008&)

26. Wang SY, Wang C, Turdi S, et al. ALDH2 protects against high fat diet-induced obesity cardiomyopathy and defective autophagy: role of CaM kinase Ⅱ, histone H3K9 methyltransferase SUV39H, Sirt1, and PGC-1α deacetylation. Int J Obes. 2018;42(5):1073–87. doi: 10.1038/s41366-018-0030-4.  [DOI](https://doi.org/10.1038/s41366-018-0030-4) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/29535452/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Int%20J%20Obes&title=ALDH2%20protects%20against%20high%20fat%20diet-induced%20obesity%20cardiomyopathy%20and%20defective%20autophagy:%20role%20of%20CaM%20kinase%20%E2%85%A1,%20histone%20H3K9%20methyltransferase%20SUV39H,%20Sirt1,%20and%20PGC-1%CE%B1%20deacetylation&author=SY%20Wang&author=C%20Wang&author=S%20Turdi&volume=42&issue=5&publication_year=2018&pages=1073-87&pmid=29535452&doi=10.1038/s41366-018-0030-4&)

27. Piechotta V, Adams A, Haque M, et al. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. Cochrane Database Syst Rev. 2021;11(11):CD012775. doi: 10.1002/14651858.CD012775.pub2.  [DOI](https://doi.org/10.1002/14651858.CD012775.pub2) | [PMC free article](/articles/PMC8594936/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/34784425/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cochrane%20Database%20Syst%20Rev&title=Antiemetics%20for%20adults%20for%20prevention%20of%20nausea%20and%20vomiting%20caused%20by%20moderately%20or%20highly%20emetogenic%20chemotherapy:%20a%20network%20meta-analysis&author=V%20Piechotta&author=A%20Adams&author=M%20Haque&volume=11&issue=11&publication_year=2021&pages=CD012775&pmid=34784425&doi=10.1002/14651858.CD012775.pub2&)

28. 王 瑛琦, 汪 小海, 葛 卫红. 基因多态性影响术后恶心呕吐的研究进展. 药学与临床研究. 2020;28(2):136–8.  [Google Scholar](https://scholar.google.com/scholar_lookup?journal=%E8%8D%AF%E5%AD%A6%E4%B8%8E%E4%B8%B4%E5%BA%8A%E7%A0%94%E7%A9%B6&title=%E5%9F%BA%E5%9B%A0%E5%A4%9A%E6%80%81%E6%80%A7%E5%BD%B1%E5%93%8D%E6%9C%AF%E5%90%8E%E6%81%B6%E5%BF%83%E5%91%95%E5%90%90%E7%9A%84%E7%A0%94%E7%A9%B6%E8%BF%9B%E5%B1%95&author=%E7%91%9B%E7%90%A6%20%E7%8E%8B&author=%E5%B0%8F%E6%B5%B7%20%E6%B1%AA&author=%E5%8D%AB%E7%BA%A2%20%E8%91%9B&volume=28&issue=2&publication_year=2020&pages=136-8&)

29. Liu YR, Tantoh DM, Lin CC, et al. Risk of gout among Taiwanese adults with ALDH-2 rs671 polymorphism according to BMI and alcohol intake. Arthritis Res Ther. 2021;23(1):115. doi: 10.1186/s13075-021-02497-9.  [DOI](https://doi.org/10.1186/s13075-021-02497-9) | [PMC free article](/articles/PMC8048165/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/33858492/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Arthritis%20Res%20Ther&title=Risk%20of%20gout%20among%20Taiwanese%20adults%20with%20ALDH-2%20rs671%20polymorphism%20according%20to%20BMI%20and%20alcohol%20intake&author=YR%20Liu&author=DM%20Tantoh&author=CC%20Lin&volume=23&issue=1&publication_year=2021&pages=115&pmid=33858492&doi=10.1186/s13075-021-02497-9&)

30. Kayaaltı Z, Söylemezoğlu T. Distribution of ADH1B, ALDH2, CYP2E16, and CYP2E17B genotypes in Turkish population. Alcohol. 2010;44(5):415–23. doi: 10.1016/j.alcohol.2010.06.002.  [DOI](https://doi.org/10.1016/j.alcohol.2010.06.002) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/20598484/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Alcohol&title=Distribution%20of%20ADH1B,%20ALDH2,%20CYP2E16,%20and%20CYP2E17B%20genotypes%20in%20Turkish%20population&author=Z%20Kayaalt%C4%B1&author=T%20S%C3%B6ylemezo%C4%9Flu&volume=44&issue=5&publication_year=2010&pages=415-23&pmid=20598484&doi=10.1016/j.alcohol.2010.06.002&)
